Targeting KRAS mutant lung cancer: light at the end of the tunnel

Targeting KRAS mutant lung cancer: light at the end of the tunnel

For decades, KRAS mutant lung adenocarcinomas (LUAD) have been refractory to therapeutic strategies based on personalized medicine owing to the complexity of designing inhibitors to selectively target KRAS and downstream targets with acceptable toxicities. The recent development of selective KRASG12...

Full description

Bibliographic Details
Main Authors: Matthias Drosten, Mariano Barbacid
Format: Article
Language:English
Published: Wiley 2022-03-01
Series:Molecular Oncology
Subjects:
genetically engineered mouse tumor models
KRASG12C inhibitors
lung adenocarcinoma
RAF1
RAS signaling
tumor resistance
Online Access:https://doi.org/10.1002/1878-0261.13168

Internet

https://doi.org/10.1002/1878-0261.13168

Similar Items